Introduction {#Sec1}
============

Conventional methods for prenatal diagnosis have been amniocentesis and chorionic villus sampling, which carry a 1% risk of miscarriage^[@CR1]--[@CR3]^. Recently, noninvasive prenatal testing (NIPT) has been gaining popularity, as it only requires maternal peripheral blood^[@CR4],[@CR5]^. NIPT is recommended as a primary trisomy screening test to all pregnant women^[@CR6],[@CR7]^. To date, several methods of NIPT have been developed, according to various needs of patients^[@CR5],[@CR8]--[@CR12]^. With the development of various methods of NIPT, its overall convenience and accuracy have also been improving. In the previous study, we developed a novel protocol of NIPT applicable to autosomal recessive (AR) monogenic disease in predicting the genotype of a fetus (second baby) based on the first baby's known genotype, using a higher-resolution picodroplet digital PCR (dPCR)^[@CR10]^.

Although our previous protocol showed successful prediction, it required calculating the fraction of fetal DNA (the second baby's fetal DNA) among the maternal plasma DNA (mpDNA) to produce simulated control samples and perform statistical analyses. In compound heterozygous genotypes, a fraction of fetal DNA can, if not always, be calculated by measuring the fraction of paternal mutation in mpDNA. However, a paternal allele-specific single nucleotide polymorphism (SNP), which does not exist in the maternal allele, should additionally be searched in homozygotes. However, this process is a time and effort-intensive task, which may not always be feasible. This process may be particularly difficult in east Asian populations where there are a lot of prevalent founder alleles, and therefore, homozygous genotypes for autosomal recessive disorders.

In our present study recruiting families segregating such homozygous AR deafness variants, we developed a novel, convenient NIPT protocol, which does not require either searching for a paternal allele specific SNP nor reconstruction of haplotypes. This protocol utilized both chi-squared test and Bayesian method, allowing for prenatal diagnosis without the calculation of fetal DNA fraction. This protocol successfully predicted fetal genotypes.

Methods {#Sec2}
=======

Subjects and Ethical Considerations {#Sec3}
-----------------------------------

The institutional review boards of both Seoul National University Hospital (IRBY-H-0905--041--281) and Seoul National University Bundang Hospital (IRB-B-1007-105-402 and IRB-B-1508-312-304) approved all procedures used in this study. All subjects provided written informed consent. All methods were performed in accordance with the relevant guidelines and regulations. Three families with the first baby already confirmed to have SNHL due to AR mutations of known deafness genes and an unborn baby (fetus) were included in this study (Supplementary Figure [S1](#MOESM1){ref-type="media"}). Causative mutation of SNHL from SH197 and SB275 families has previously been documented as *GJB2* c.235delC homozygote through bioinformatic analysis as described^[@CR13],[@CR14]^. The causative mutation of SNHL from SH162 family has previously been documented as *SLC26A4* c.IVS7-2A \> G. NIPT was performed for genotyping of the causative deafness gene from the unborn baby of each family.

Plasma DNA extraction protocol {#Sec4}
------------------------------

Blood samples were collected from all pregnant mothers. At the time of this procedure, the maternal gestational ages of SH197, SB275, and SH162 families were 16, 27 and 16 weeks, respectively. The maternal body weights were 48, 55, and 51 kg, respectively. Plasma DNA was extracted as described^[@CR10]^; 1.5 ml plasma was added to a microcentrifuge tube and centrifuged for 10 min at 2000 g using MACHEREY-NAGEL, NucleoSpin Plasma XS (Germany) kit. Circulating DNA was extracted following the manufacturer's guidelines.

gDNA preparation {#Sec5}
----------------

gDNA was prepared as described^[@CR15]^. The control samples were made with gDNA previously obtained from the mother, and first baby in each family. To make the size of gDNA close to the size of plasma DNA, gDNA was fragmented using Covaris S220 (Covaris, MA, USA). The fragment size was confirmed as 150 base pair length by Bioanalyzer High Sensitivity DNA Chips (Agilent Technologies, CA, USA). DNA concentration was measured using a fluorescence assay of Picogreen (Invitrogen, Grand Island, NY, USA).

Picodroplet digital PCR (dPCR) methods {#Sec6}
--------------------------------------

Picodroplet dPCR was performed using RainDrop Digital PCR System (RainDance Technologies Inc., Billerica, MA, USA), as previously described^[@CR10]^. PCR reaction mixes consisted of primers and probes (Supplementary Table [S1](#MOESM1){ref-type="media"} and Supplementary Figure [S2](#MOESM1){ref-type="media"}) along with 12.5 µl TaqMan Genotyping Master Mix (Life Technologies), 1.25 µl Drop Stabilizer (RainDance Technologies), DNase/RNase-free sterile water, and template DNA (either the minimum 2 ng of plasma DNA or 30 ng of the fragmented gDNA), making up a total reaction volume of 25 µl. Each 25 µl PCR mix was emulsified into 5 pl droplet volumes using RainDrop Source instrument (RainDance Technologies). A single molecule of DNA was partitioned into approximately 5 million droplets. Then, PCR mixes were placed in a C1000 with deep-well (Bio-Rad) and amplified, according to the protocol (Supplementary Table [S2](#MOESM1){ref-type="media"}). The fluorescent intensity of each droplet for two fluorophores (FAM and VIC) was identified using RainDrop Sense instrument (RainDance Technologies). The data from cluster plots were analyzed using RainDrop Analyst data analysis software, as previously described^[@CR10]^.

Chip-based dPCR methods {#Sec7}
-----------------------

QX200 Droplet digital PCR System (Bio-Rad Laboratories, Inc., Hercules, CA USA) was used to assess nanodroplet dPCR. In a pre--polymerase chain reaction environment, PCR reaction mixes were combined with primers and probes (Supplementary Table [S3](#MOESM1){ref-type="media"}) along with 10 μl TaqMan Genotyping Master Mix (Life Technologies), DNase/RNase-free sterile water, and template DNA (either the minimum 700 pg of plasma DNA or 30 ng of the fragmented gDNA), which made up a total reaction volume of 20 μl. A probe was validated (Supplementary Figure [S2](#MOESM1){ref-type="media"}). Droplets were then generated using DG8 droplet generator cartridges by mixing the aqueous phase with 70 mL of droplet generation oil (Bio-Rad Laboratories). Each 20 μl PCR mix was emulsified into about 1 nl droplet volumes, partitioning a few molecules of DNA into approximately 20 thousand droplets. Droplets were transferred to a 96-well PCR plate and then sealed using the PX1 PCR plate sealer (Bio-Rad Laboratories) for 5 seconds at 180 degree before thermal cycling. The PCR plate was placed in a C1000 Touch thermal cycler with deep-well (Bio-Rad Laboratories) to be amplified, following the protocol outlined in Supplementary Table [S4](#MOESM1){ref-type="media"}. After thermal cycling, the PCR plate that included droplets was loaded onto QX200 Droplet Reader instrument (Bio-Rad laboratories), identifying the fluorescent intensity of each droplet for two fluorophores (FAM and VIC) simultaneously using Multi-pixel photon counter. This detector reads the droplets to determine the ones that contain a target gene (+) and the ones that do not (−), and plots the fluorescence droplet by droplet. The fraction of positive droplets in a sample determines the concentration of target in copies/μl.

Noninvasive prenatal testing (NIPT) protocol {#Sec8}
--------------------------------------------

We used both the gatekeeping method and Bayesian method to predict the genotype status of the fetus. The gatekeeping method was composed of chi-squared test and comparison of a proportion of the mutant allele reads among the total reads (*θ*) against the empirical range of the proportion from a heterozygous genotype, and it facilitated fast decision. The Bayesian method was based on prior information and data distribution, and robust decision was expected (Fig. [1](#Fig1){ref-type="fig"}).Figure 1Protocol of noninvasive prenatal diagnosis. \*The cutoff value of Bayes factor is 0.7 for picodroplet dPCR and 1 for chip-based dPCR. BF, Bayes factor.

In the gatekeeping method, chi-squared test of the plasma sample against the simulated heterozygous control was initially conducted. Maternal gDNA was used as the heterozygous control sample. When dPCR was performed on several samples from one subject, the observed mutant allele proportion was calculated by summing the mutant reads with the total droplet reads in each sample. The heterozygous control was expected to have a wild: mutant allele reads ratio of 50:50; rejecting the null hypothesis of chi-squared test indicated that the plasma sample is more likely to be either wild or mutant homozygote. To rule out any false negative results from chi-squared test due to errors and a small number of reads from dPCR, value of *θ* less than 48% or greater than 52% was regarded as a wild or mutant homozygous. This empirical range of the heterozygous genotype was obtained from a hypothetical range of the fetus DNA fraction (2.5--11%) and a statistical simulation assuming a normal experimental error rate of 1.0% (standard deviation 0.025%) and 1.5% (standard deviation 0.5%) for picodroplet and chip-based dPCR, respectively. The mean and standard deviation of error were obtained from simulated control with known a fetus DNA fraction. As the effect caused by the difference in the error rate between picodroplet and chip-based dPCR was not significant, the same range was applicable for both methods. Consequently, if a P-value from chi-squared test was less than 0.05 and the value of θ was less than 48% or more than 52%, the result was considered conclusive in the gatekeeping method. If not, the diagnosis was made considering a Bayesian method.

For the Bayesian method, a single droplet read was assumed to be generated from the Bernoulli trial. A mutant allele read was considered as a success. *θ* was necessarily affected by the amount of fetus DNA in the total plasma DNA (*p*). We introduced three genotype statuses of the fetus (*G*); a wildtype (*G* = 1) with *θ* = (1-*p*)/2, a single heterozygote (*G* = 2) with *θ* = 1/2, and a homozygous mutant (*G* = 3) with *θ* = (1 + *p*)/2. Prior information of three genotypes denoted as $\documentclass[12pt]{minimal}
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                \begin{document}$$\pi (G)$$\end{document}$ was 0.25 (*G* = 1), 0.5 (*G* = 2), and 0.25 (*G* = 3), respectively. The priors imply the genotype is determined by the Mendelian inheritance. Prior information of *p*, $\documentclass[12pt]{minimal}
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                \begin{document}$$\pi (p)$$\end{document}$, was assumed to follow the Beta distribution with α = 4 and ß = 100. It means that the prior mean of the amount of fetus DNA contained in the total plasma DNA was set as 4%. The observed mutant allele proportion of the *i*th sample was defined as mutant reads (*x*~*i*~) out of the total droplet reads (*n*~*i*~). When dPCR was performed on several samples from one subject, the observed mutant allele proportion was calculated by summing *x*~*i*~ and *n*~*i*~ in each sample. The posterior distribution of *G* can be calculated based on the experimental values as follows; $\documentclass[12pt]{minimal}
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                \begin{document}$$\pi (p,\,G|x)\propto \,(\begin{array}{c}N\\ x\end{array})\,{(\theta (G,p))}^{x}{(1-\theta (G,p))}^{\{N-x\}}\times \,\pi (G)\times \pi (p)$$\end{document}$. We conducted the Bayesian hypothesis test using the Bayes factor, which is a ratio of two competing hypotheses; a higher value indicates the favorability of the alternative hypothesis over the null hypothesis. In our study, the null hypothesis was that the fetus was either a wildtype or a single heterozygote, whereas the alternative hypothesis was that the fetus was a homozygous mutant. If the Bayes factor of a homozygous mutant (*G* = 3) over a wildtype or a single heterozygote (*G* = 1 or 2) was greater than the cutoff value, the alternative hypothesis -- homozygous mutant -- was accepted.

To determine the cutoff value for the Bayes factor, we simulated both numerical and experimental studies. We made three types of biological control samples mimicking the wildtype, homozygous mutant, and heterozygote in each family. The homozygous mutant and wildtype control samples indicated the maternal gDNA with and without a homozygous mutation in a proportion of 5.6%, respectively. We used the first baby's gDNA as the gDNA components with homozygous mutation. Maternal gDNA was used as the heterozygote control sample. Several datasets were computationally simulated based on the same assumption for the gatekeeping method; the error rate followed normal a distribution with a mean of 1.0% and a standard deviation of 0.025% for picodroplet dPCR and a mean of 1.5% and a standard deviation of 0.5% for chip-based dPCR; the various fetus DNA fraction ratios ranged from 2.5% to 11%. The cutoff value of Bayes factor was determined to be 0.7 for picodroplet dPCR and 1 for chip-based dPCR, since this cutoff provided 100% specificity and 90% sensitivity in our simulated data when the number of read copy was at least 1,000.

We developed a diagnostic protocol using both the gatekeeping method and Bayesian method. The former was first performed to obtain the quick diagnosis, if applicable. If the gatekeeping method yielded inconclusive results, the Bayesian method was conducted. Finally, results from both methods were considered (Fig. [1](#Fig1){ref-type="fig"}). Statistical analyses were performed using R 3.4.1.

Confirmation of fetal genotype after birth {#Sec9}
------------------------------------------

In the SH197 family, peripheral blood samples were obtained from the second baby after birth. Allele-specific PCR-based universal array (CapitalBio Corporation, Beijing, China) was applied to targeted the gene^[@CR11]^. In SB275 and SH162 families, Sanger sequencing of gDNA from buccal mucosa of the second baby was performed to sequence the target residue after birth. The predicted fetal genotypes were checked against these results.

Results {#Sec10}
=======

Prediction of fetal genotypes by our NIPT protocol {#Sec11}
--------------------------------------------------

In the SH197 and SB275 families, father and mother were single heterozygous carriers of *GJB2* c.235delC, and the first babies were homozygotes of c.235delC in *GJB2*. In the SH162 family, father and mother were single heterozygous carriers of *SLC26A4* IVS7-2A \> G, and the first babies were homozygotes of IVS7-2A \> G in *SLC26A4* (Supplementary Figure [S1](#MOESM1){ref-type="media"}).

In the SH197 family, a chi-squared test was conducted and *θ* of plasma sample was significantly lower than that of the heterozygous control (*P* = 0.001). *θ* of plasma sample (344/786 (43.77%)) was less than 48%. The fetus was diagnosed as a wildtype genotype (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}Table 1The results of noninvasive prenatal testing using digital PCR.FamilyProbedPCR methodSampleTotal dropletMutant readTotal readCorresponding histogramSum of mutant readSum of total readBayes factorSH197*GJB2* c.235delCpicodroplet dPCRWildtype control44072151148823677Fig. [2(A)](#Fig2){ref-type="fig"}11488236770.000Heterozygote control43454421143723111Fig. [2(B)](#Fig2){ref-type="fig"}24188486290.00147081791275125518Fig. [2(C)](#Fig2){ref-type="fig"}Homozygote control46178761461528368Fig. [2(D)](#Fig2){ref-type="fig"}28844560453488318818.00046307341422927677Fig. [2(E)](#Fig2){ref-type="fig"}Maternal plasma DNA3718365149342Fig. [2(F)](#Fig2){ref-type="fig"}344786-4441402195444Fig. [2(G)](#Fig2){ref-type="fig"}SB275*GJB2* c.235delCpicodroplet dPCRWildtype control415294113552801Supplementary Figure [S3(A)](#MOESM1){ref-type="media"}272956500.000423626513742849Supplementary Figure [S3(B)](#MOESM1){ref-type="media"}Heterozygote control414049612612537Supplementary Figure [S3(C)](#MOESM1){ref-type="media"}126125370.083Homozygote control387523214242771Supplementary Figure [S3(D)](#MOESM1){ref-type="media"}298057814.802417474615563010Supplementary Figure [S3(E)](#MOESM1){ref-type="media"}Maternal plasma DNA4357569521981Supplementary Figure [S3(F)](#MOESM1){ref-type="media"}1068200714.88544102225471026Supplementary Figure [S3(G)](#MOESM1){ref-type="media"}SH162*SLC26A4* IVS7-2A \> Gpicodroplet dPCR, 1st trialWildtype control420343121114487Supplementary Figure [S4(A)](#MOESM1){ref-type="media"}390182940.000404425517903807Supplementary Figure [S4(B)](#MOESM1){ref-type="media"}Heterozygote control406304723304663Supplementary Figure [S4(C)](#MOESM1){ref-type="media"}233046630.070Homozygote control429536228215335Supplementary Figure [S4(D)](#MOESM1){ref-type="media"}5409102273304799.523406193925884892Supplementary Figure [S4(E)](#MOESM1){ref-type="media"}Maternal plasma DNA346082855104Supplementary Figure [S4(F)](#MOESM1){ref-type="media"}128242-445948273138Supplementary Figure [S4(G)](#MOESM1){ref-type="media"}picodroplet dPCR, 2nd trialWildtype control416478416223444Supplementary Figure [S5(A)](#MOESM1){ref-type="media"}162234440.000Heterozygote control387736616133243Supplementary Figure [S5(B)](#MOESM1){ref-type="media"}370073810.065462709920874138Supplementary Figure [S5(C)](#MOESM1){ref-type="media"}Maternal plasma DNA4040299302569Supplementary Figure [S5(D)](#MOESM1){ref-type="media"}61611602.8894130434314591Supplementary Figure [S5(E)](#MOESM1){ref-type="media"}chip-based dPCR, 1st trialWildtype control1568814743014Supplementary Figure [S6(A)](#MOESM1){ref-type="media"}147430140.020Heterozygote control1711415973214Supplementary Figure [S6(B)](#MOESM1){ref-type="media"}291158710.0241424713142657Supplementary Figure [S6(C)](#MOESM1){ref-type="media"}Maternal plasma DNA12516135257Supplementary Figure [S6(D)](#MOESM1){ref-type="media"}135257-chip-based dPCR, 2nd trialWildtype control1472416003373Supplementary Figure [S7(A)](#MOESM1){ref-type="media"}330269690.0001496417023596Supplementary Figure [S7(B)](#MOESM1){ref-type="media"}Heterozygote control1649319303965Supplementary Figure [S7(C)](#MOESM1){ref-type="media"}193039650.007Homozygote control1680920163853Supplementary Figure [S7(D)](#MOESM1){ref-type="media"}403476931944.1771604020183840Supplementary Figure [S7(E)](#MOESM1){ref-type="media"}Maternal plasma DNA1625365115Supplementary Figure [S7(F)](#MOESM1){ref-type="media"}139246-1760174131Supplementary Figure [S7(G)](#MOESM1){ref-type="media"}Maternal gDNA artificially containing the gDNA components without and with homozygous mutation in 5.6%, respectively, was used as the wildtype and homozygote control. The first baby's gDNA was used as the gDNA components with homozygous mutation. Maternal gDNA was used as the heterozygote control sample. If the total read count was less than 1,000, the Bayes factor was not calculated. dPCR, digital PCR; gDNA, genomic DNA.).Table 2Diagnostic results of noninvasive prenatal testing using digital PCR.FamilydPCR methodProportion of the mutant allele reads among the total reads in the plasma sampleProportion of the mutant allele reads among the total reads in the heterozygous control sampleP-value of Chi-squared testProportion of the mutant allele reads among the total reads \<48% or \>52%Bayes factor of plasma sampleDiagnosisSH197picodroplet digital PCR344/786 (43.77%)24,188/48,629 (49.74%)0.001Yes---Wildtype genotypeSB275picodroplet digital PCR1,068/2,007 (53.21%)1,261/2,537 (49.70%)0.018Yes14.885Homozygous genotypeSH162picodroplet dPCR, 1st trial128/242 (52.89%)2330/4663 (49.97%)0.379Yes---Probably homozygous genotypepicodroplet dPCR, 2nd trial616/1160 (53.10%)3700/7381 (50.13%)0.411Yes2.889Homozygous genotypechip-based dPCR, 1st trial135/257 (52.53%)2911/5871 (49.58%)0.389Yes---Probably homozygous genotypechip-based dPCR, 2nd trial139/246 (56.50%)1930/3965 (48.68%)0.020Yes---Homozygous genotypeFigure 2Two-dimensional histogram of the mutation (*GJB2* c.235delC) in wildtype (**A**), heterozygote (**B**,**C**) and homozygote (**D**,**E**) controls and maternal plasma DNA (**F**,**G**) of SH197 family.

In the SB275 family, a chi-squared test was conducted and *θ* of plasma sample was significantly higher than that of the heterozygous control (*P* = 0.018). *θ* of plasma sample (1,068/2,007 (53.21%)) was more than 52%. The fetus was diagnosed as homozygous genotype (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} and Supplementary Figure [S3](#MOESM1){ref-type="media"}). The prenatal diagnosis was obtained from the gatekeeping method, but the Bayesian method was conducted to verify the results from the gatekeeping method. The two plasma samples were tested, and the sum of mutant reads and total droplet reads were 1,068 and 2,007, respectively, resulting in a Bayes factor of 14.885. The fetus was diagnosed as homozygous genotype consistent with the result of the gatekeeping method (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} and Supplementary Figure [S3](#MOESM1){ref-type="media"}).

In the SH162 family, we conducted several experiments using picodroplet and chip-based dPCR. According to our first result from picodroplet dPCR, *θ* of plasma sample showed no significant difference when compared with that of the heterozygous control (*P* = 0.379), although *θ* of plasma sample (128/242 (52.89%)) was more than 52%. As the number of read copy was less than 1,000, the Bayesian method was not conducted. The fetus was diagnosed as a homozygous genotype, without certainty (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} and Supplementary Figure [S4](#MOESM1){ref-type="media"}). As this result was inconclusive, we conducted dPCR once more using picodroplet dPCR. According to our second result from picodroplet dPCR, *θ* of plasma sample showed no significant difference when compared with that of the heterozygous control (*P* = 0.411), although *θ* of plasma sample (616/1160 (53.10%)) was more than 52%. The Bayesian method was conducted, resulting in a Bayes factor of 2.889. The fetus was diagnosed as a homozygous genotype (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} and Supplementary Figure [S5](#MOESM1){ref-type="media"}).

As for the chip-based dPCR, our first result showed that there was no significant difference of *θ* between the plasma sample and the heterozygous control (*P* = 0.389), although *θ* of plasma sample (135/257 (52.53%)) was more than 52%. As the number of read copy was less than 1,000, the Bayesian method was not conducted. The fetus was diagnosed as likely having a homozygous genotype (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} and Supplementary Figure [S6](#MOESM1){ref-type="media"}). Given the inconclusive result, we conducted dPCR once more using chip-based dPCR. According to our second result from chip-based dPCR, *θ* of plasma sample was significantly higher than that of the heterozygous control (*P* = 0.018); *θ* of plasma sample (139/246 (56.50%)) was more than 52%. The fetus was diagnosed as homozygous genotype (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} and Supplementary Figure [S7](#MOESM1){ref-type="media"}). The diagnosis using chip-based dPCR was consistent with using picodroplet dPCR.

Genetic study for confirmation of fetal genotype {#Sec12}
------------------------------------------------

In the SH197 family, allele-specific PCR-based universal array from the second baby confirmed a wildtype of *GJB2* c.235delC^[@CR16]^. In the SB275 and SH162 families, Sanger sequencing from the second baby confirmed a homozygous mutant of *GJB2* c.235delC and *SLC26A4* IVS7-2A \> G, respectively **(**Fig. [3](#Fig3){ref-type="fig"}**)**. The prenatal diagnosis for the second babies in all families was correct.Figure 3Genetic study for confirmation of fetal genotype. (**A**) Sanger sequencing traces of the second-born baby of SB275 family: *GJB2* c.235delC homozygote. (**B**) Sanger sequencing traces of the second-born baby of SH162 family: *SLC26A4* IVS7-2A \> G.

Discussion {#Sec13}
==========

After discovering the cell-free fetal DNA (cffDNA) in the peripheral blood of pregnant women^[@CR17]^, there has been tremendous development in the prenatal diagnosis using cffDNA^[@CR8],[@CR12],[@CR18]^. The first NIPT using cffDNA was performed to determine fetal sex^[@CR17]^ and RhD status^[@CR19],[@CR20]^. The application of NIPT was extended from aneuploidies, such as trisomy 21, to monogenic diseases^[@CR8],[@CR10],[@CR18],[@CR21],[@CR22]^. The expansion of NIPT applicability has been attributed to the improvement of technology and strategy of NIPT. The representative techniques of NIPT are massive parallel sequencing (MPS)^[@CR23]^ and dPCR^[@CR8],[@CR12]^.

NIPT using targeted MPS technology has also been performed by the reconstruction of fetal haplotypes, which required sequencing numerous single nucleotide polymorphisms (SNPs) around the residue of interest^[@CR24]--[@CR28]^. Recombination of fetal alleles has often made NIPT more complicated. Recently, it has been shown that the reconstruction of only the paired end allelic reads suffice for NIPT^[@CR4],[@CR5]^. However, it is not possible to make the whole process of MPS technology for NIPT any simpler or shorter, regardless of the frequency of target mutation. The second NIPT technique using dPCR makes it possible to genotype the residue of interest directly. It may relatively be simpler and more straightforward than NIPT using MPS. Once we are well equipped with probes and primers for dPCR, with reaction conditions that have been well calibrated for certain founder mutations, then subsequent NIPT testing that targets a specific mutation may be easier and less time consuming to perform. Therefore, this technology is especially convenient for testing highly prevalent AR variants. Moreover, in our previous study, we showed that the accuracy of NIPT was further improved by utilizing picodroplet dPCR, which guarantees higher resolution^[@CR10]^. However, there were procedural difficulties, especially in homozygous genotypes. In our previous protocol, prenatal diagnosis was determined by comparing the mutant fraction of the study sample with those of positive and negative controls^[@CR10]^. The production of positive and negative controls was essential for the previous protocol, which can only be obtained via the calculation of the fraction of fetal DNA in mpDNA. In case that the maternal and the paternal mutation are different from each other, the fraction of fetal DNA in mpDNA can be calculated easily by measuring the fraction of the paternal mutant residue in mpDNA, if the fetus inherits the paternal mutation. However, in homozygous genotypes, both paternal and maternal mutations are identical; hence, the fraction of fetal DNA in mpDNA cannot be calculated simply by measuring the fraction of the paternal mutant residue in mpDNA. SNPs (more preferably, homozygous SNPs) that exist exclusively in the paternal gDNA, but not in the maternal gDNA, should be searched. This requires additional cost and time. To circumvent this issue, we developed a novel protocol for diagnosing the fetal genotype in homozygous genotypes without needing any information regarding the fraction of fetal DNA in mpDNA.

Theoretically, in determining genotypes of homozygous AR variants we can predict the genotype of a fetus based on the proportion of mutant allele reads among total reads in mpDNA: a proportion of mutant allele reads of less than 50% is considered a wildtype; a proportion of mutant allele reads that equals 50% is considered a single heterozygote; and a proportion of mutant allele reads of greater than 50% is considered a homozygote. However, since no test is perfectly precise, we must take in to account for any test errors. For example, we may consider two possibilities when a proportion of mutant allele reads is measured to be 50.5%. The first interpretation is that we can regard the proportion to have some experimental error and consider the genotype to be a single heterozygote. The second one is to consider the genotype to be a mutant homozygous, with a fairly small amount of fetus DNA in mpDNA. To distinguish these possibilities statistically, we employed a comprehensive simulation study for both the gatekeeping method and Bayesian method. We assumed the error rate to be within a normal distribution and a fetus DNA fraction to be within a range from 2.5% to 11%. The simulated data was used to determine an empirical range of mutant read proportion. The genotype of a fetus was expected to be wild or mutant homozygous when the proportion of mutant allele reads of mpDNA was smaller than 48% or greater than 52%, respectively, with a *P*-value from chi-squared test set to less than 0.05. We also generated simulated data for deciding the cutoff value for the Bayesian method. The Bayes factor cutoff value −0.7 for picodroplet dPCR and 1 for chip-based dPCR -- was then tested for three types of control samples with known membership information and these proposed values worked successfully for prediction of genotypes of the control samples. Our numerical simulation showed that the proposed cutoff value was applicable to all cases with *GJB2* c.235delC and c.*SLC26A4* IVS7--2A \> G mutation, under the condition that the total droplet read counts in dPCR is greater than or equal to 1,000 for statistical significance. Therefore, in the case of *GJB2* c.235delC and *SLC26A4* IVS7-2A \> G, prenatal diagnosis can be made by examining only mpDNA in a single step, without further simulation. Expanding the scope further, if the cutoff value of Bayes factor is calculated for other prevalent homozygous mutations in this manner, a rapid diagnosis may likely be possible just from obtaining the maternal peripheral blood sample.

Another important implication of this study is that the improved NIPT protocol described in this paper successfully predicted the fetal genotypes using the chip-based dPCR platform. Although picodroplet dPCR has a higher resolution than chip-based dPCR, it is not widely available. If the NIPT protocol is only available using picodroplet dPCR, it may be difficult for most clinics to adopt this protocol, thus limiting the popularization. In this sense, our NIPT protocol coupled with chip-based dPCR and the gatekeeping method is expected to be more widely used and contribute to the popularization of NIPT.

As technology further develops, prenatal diagnosis will become more popular, with increased benefits. Our study shows that NIPT for all monogenic diseases could be easily performed by simply taking peripheral blood samples and performing quick statistical tests using the data generated from readily available chip-based dPCR, if the genotype of the first baby is available.
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